振源胶囊辅助治疗不稳定型心绞痛的临床疗效及对血NT-proBNP、HCY水平的影响

Clinical Efficacy of Zhenyuan Capsule in Adjuvant Treatment of Unstable Angina Pectoris and its Effect on Blood NT-proBNP and HCY Levels

目的 观察振源胶囊辅助治疗不稳定型心绞痛的临床疗效及对血氨基末端B型利钠肽前体(NT-proBNP)、同型半胱氨酸(HCY)水平的影响。方法 选取2019年6月-2021年12月我院诊治的82例不稳定型心绞痛患者为研究对象,采用随机数字表法分为对照组和观察组,各41例。对照组采用常规治疗,观察组在对照组基础上给予振源胶囊辅助治疗,比较两组临床疗效、NT-proBNP、HCY、心电图疗效、心绞痛发作次数、心绞痛持续时间、超敏C反应蛋白(hs-CRP)、空腹血糖水平以及临床不良反应发生情况。结果 观察组治疗总有效率为95.12%,高于对照组的80.49%(P<0.05);观察组血NT-proBNP、HCY水平低于对照组(P<0.05);观察组心电图总有效率为92.68%,高于对照组的78.05%(P<0.05);观察组心绞痛发作次数、心绞痛持续时间均小于对照组(P<0.05);观察组hs-CRP、空腹血糖水平低于对照组(P<0.05);观察组不良反应发生率为7.32%,与对照组的9.76%比较,差异无统计学意义(P>0.05)。结论 振源胶囊辅助治疗不稳定型心绞痛的疗效良好,可提高治疗总有效率和心电图总有效率,改善心电图ST-T段缺血,减少心绞痛发作次数和持续时间,降低血清NT-proBNP、HCY、hs-CRP以及血糖水平,且不会增加不良反应。

Objective To observe the clinical efficacy of Zhenyuan capsules in adjuvant treatment of unstable angina pectoris and its effect on the levels of N-terminal B-type natriuretic peptide(NT-proBNP) and homocysteine(HCY).Methods A total of 82 patients with unstable angina pectoris diagnosed and treated in our hospital from June 2019 to December 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 41 cases in each group. The control group was treated with conventional therapy, and the observation group was treated with Zhenyuan capsule on the basis of the control group. The clinical efficacy, NT-proBNP, HCY, electrocardiogram efficacy, number of angina pectoris attacks, duration of angina pectoris, high-sensitivity C-reactive protein(hs-CRP), fasting blood glucose level and clinical adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.12%,which was higher than 80.49% in the control group(P<0.05). The levels of NT-proBNP and HCY in the observation group were lower than those in the control group(P<0.05). The total effective rate of ECG in the observation group was 92.68%, which was higher than 78.05% in the control group(P<0.05). The frequency and duration of angina pectoris in the observation group were less than those in the control group( P<0.05). The levels of hsCRP and fasting blood glucose in the observation group were lower than those in the control group(P<0.05). The incidence of adverse reactions in the observation group was 7.32%, which was compared with 9.76% in the control group, the difference was not statistically significant( P >0.05).Conclusion Zhenyuan capsule is effective in the adjuvant treatment of unstable angina pectoris, which can improve the total effective rate of treatment and the total effective rate of electrocardiogram, improve the ST-T segment ischemia of electrocardiogram, reduce the frequency and duration of angina pectoris, and reduce serum NT-proBNP, HCY, hs-CRP and blood glucose levels, without increasing adverse reactions.